易曉芳

易曉芳，主任醫師。現任復旦大學附屬婦產科醫院普通婦科主任。

從事婦產科臨床工作20餘年，曾在美國Arizona Cancer Center從事相關博士後研究。

基本介紹

• 中文名：易曉芳
• 臨床職稱：主任醫師
• 執業地點：復旦大學附屬婦產科醫院

擅長領域

婦科各種良、惡性疾患、以及疑難雜症的診斷與微創手術治療，包括各種類型子宮內膜異位症、子宮腺肌症、子宮肌瘤、卵巢囊腫、盆腔腫塊、宮頸癌、子宮體癌、卵巢癌等。

研究方向

子宮內膜異位症/深部浸潤型發病機制探討、以及多學科團隊微創規範診治；卵巢癌耐藥機制探索。

發表文章

以第一/通訊作者發表論文30餘篇。主要如下。

1. Yi XF, Yuan ST, Ding J, Feng YJ. A clinically relevant orthotopic implantation nude mouse model of human epithelial ovarian cancer---based on consecutive observation. Int J Gynecol Cancer, 2005, 15(5): 850-855.10．

2. Yi XF, Fan SM, Yao M, Feng YJ. Comparison of efficacy and toxicity profile between intraperitoneal and intravenous topotecan in human ovarian cancer xenografts. Beijing Da Xue Xue Bao. 2006, 38(1):88-91.

3. Fadare O, Yi X#, Liang SX, Ma Y, Zheng W. Variations of mitotic index in normal and dysplastic squamous epithelium of the uterine cervix as a function of endometrial maturation. Mod Pathol. 2007, 20(9):1000-1008.

4. Yi X, Zhou Y, Zheng W, Chambers SK. HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer. Aust N Z J Obstet Gynaecol. 2009, 49(1):93-98.

5. Liao H, Zhou Q, Zhang Z, Wang Q, Sun Y, Yi X*, Feng Y*. NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones. Oncology Reports, 2012, 27(6): 1918-1924.

6. Lu Z#,, Yi X#, Feng W, Ding J, Xu H, Zhou X, Hua K. Cost-effective analysis of laparoscopic surgery versus laparotomy for patients with endometrioid endometrial cancer: Experience from an institute in China J Obstet Gynaecol Res. 2012, 38(7): 1011-1017.

7. Bao L, Jaramillo MC, Zhang Z, Zheng Y, Yao M, Zhang DD , Yi X*. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol, 2014,7(4):1502-1513.

8. Bao L, Jaramillo MC, Zhang Z, Zheng Y, Yao M, Zhang DD , Yi X*. Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells. Mol Med Rep, 2015, 11(1): 91-98.

9. Zheng Y, Bao L, Ning Y, Lu X, Hua K, Yi X*. Retrospective analysis of the clinicopathologic and prognostic characteristics of stage I placental site trophoblastic tumor in China. Int J Gynaecol Obstet, 2015, 129(1): 67-70.

10. Yi X, Ding J, Zhang Y, Liu X, Cheng H, Li X, Zhou X, Hua K. Laparoscopic radical trachelectomy followed by chemotherapy in a pregnant patient with invasive cervical cancer. Int J Gynaecol Obstet, 2015, 2015,131(1)’;101-102.

11. Bao L, Ding Y, Cai Q, Ning Y, Hu W, Xue X, Sun H, Hua K, Zhou X, Yi X*. Primary Fallopian Tube Carcinoma: A Single-Institution Experience of 101 Cases: A Retrospective Study.Int J Gynecol Cancer. 2016, 26(3):424-30.

12. Chen Y, Ren YL, Li N, Yi XF*, Wang HY*. Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis.Eur Rev Med Pharmacol Sci. 2016 May;20(10):1974-85.

13. Bao L, Wu J, Dodson M, Rojo de la Vega EM, Ning Y, Zhang Z, Yao M, Zhang DD, Xu C, Yi X*. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.Mol Carcinog. 2017 Jun;56(6):1543-1553.

14. Dhakal S, Zheng YX, Yi XF*. Current Updates on Salpingectomy for the Prevention of Ovarian Cancer and Its Practice Patterns Worldwide.Chin Med Sci J. 2017 Sep 27;32(3):185-192.

15. Wu J, Bao L, Zhang Z, Yi X*. Nrf2 induces cisplatin resistance via suppressing the iron export related gene SLC40A1 in ovarian cancer cells.Oncotarget. 2017 Jul 25;8(55):93502-93515.

16. Zheng Y, Zhang N, Lu W, Zhang L, Gu S, Zhang Y, Yi X*, Hua K*. Rectovaginal fistula following surgery for deep infiltrating endometriosis: Does lesion size matter? J Int Med Res. 2018 Feb;46(2):852-864.

著作譯作

參加《子宮內膜異位症》、《實用婦產科學》、《Bonney婦科手術學》等專著的編寫與翻譯。

科研項目

主持國家自然科學基金委、上海市科委等科研項目，主要如下。

國家自然科學基金面上項目：2019.1.1-2022.12.31（57萬） Nrf2-ARE信號通路活化介導鐵過載及抑制鐵死亡參與卵巢癌順鉑耐藥的機制研究。

國家自然科學基金青年基金項目：2014.1.1-2016.12.31（23萬）Nrf2-Keap1信號通路與自噬在卵巢癌順鉑耐藥中的串話。

上海市醫學引導項目：2014.10.1-2017.9.30（20萬）人源腫瘤移植模型的構建及其在卵巢癌藥物靶點篩選中的初步套用。